Illumina, Inc. (ILMN)
Market Cap | 19.18B |
Revenue (ttm) | 4.49B |
Net Income (ttm) | -1.29B |
Shares Out | 159.30M |
EPS (ttm) | -8.15 |
PE Ratio | n/a |
Forward PE | 44.83 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,412,383 |
Open | 118.56 |
Previous Close | 117.30 |
Day's Range | 117.76 - 123.87 |
52-Week Range | 86.58 - 190.31 |
Beta | 1.15 |
Analysts | Buy |
Price Target | 159.39 (+32.35%) |
Earnings Date | Aug 6, 2024 |
About ILMN
Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regio... [Read more]
Financial Performance
In 2023, Illumina's revenue was $4.50 billion, a decrease of -1.75% compared to the previous year's $4.58 billion. Losses were -$1.16 billion, -73.64% less than in 2022.
Financial StatementsAnalyst Forecast
According to 19 analysts, the average rating for ILMN stock is "Buy." The 12-month stock price forecast is $159.39, which is an increase of 32.35% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/t/g/conf8-2532704.jpg)
Illumina to Present Upcoming Strategy Update
SAN DIEGO , July 18, 2024 /PRNewswire/ -- As Illumina, Inc. (NASDAQ: ILMN) previously announced on June 24, the company will present a Strategy Update on Tuesday, August 13, 2024 starting at 8:00am Pa...
![](https://cdn.snapi.dev/images/v1/l/w/press19-2532141.jpg)
Illumina Ventures Adds Two New Experts as Advisors
SAN FRANCISCO--(BUSINESS WIRE)-- #biotech--Illumina Ventures today announced that Timothy Stenzel, MD, PhD, and Jerry Steiner have joined the team as Advisors.
![](https://cdn.snapi.dev/images/v1/g/o/whats-happening-with-illumina--2521410.jpg)
What's Happening With Illumina Stock?
Illumina stock (NASDAQ: ILMN) saw a 6% rise on Wednesday, July 10, faring better than its peer — Mettler-Toledo stock – up 1%. The rise in ILMN stock can primarily be attributed to the company's acqui...
![](https://cdn.snapi.dev/images/v1/h/s/conf17-2520686.jpg)
Illumina to Announce Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
SAN DIEGO , July 11, 2024 /PRNewswire/ -- As Illumina, Inc. (NASDAQ:ILMN) previously announced on June 24, the company will issue results for the second quarter 2024 following the close of market on T...
![](https://cdn.snapi.dev/images/v1/s/t/medical18-2518049.jpg)
Illumina Buys Fluent BioSciences To Gain Stronger Foothold In Single-Cell Analysis
Last month, Illumina Inc ILMN had to let go of Grail Inc. Still, the DNA sequencing company has acquired Fluent BioSciences to expand its reach in single-cell analysis and multiomics research.
![](https://cdn.snapi.dev/images/v1/d/e/press17-2516000.jpg)
Illumina acquires Fluent BioSciences to accelerate single-cell analysis and discovery to a broader customer base
Accessible, highly scalable single-cell technology expands Illumina's multiomics capabilities SAN DIEGO , July 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing...
![](https://cdn.snapi.dev/images/v1/k/n/medical24-2502396.jpg)
Illumina Takes a $1.47 Billion Charge Related to Its Spinoff of GRAIL
The breakup with GRAIL (GRAL) was costly for Illumina (ILMN).
![](https://cdn.snapi.dev/images/v1/v/1/medical15-2500964.jpg)
Illumina to take $1.47 bln goodwill impairment charge related to Grail in Q2
Illumina said on Thursday it will take a goodwill impairment charge of $1.47 billion in the second quarter related to the recently spun-off Grail Inc.
![](https://cdn.snapi.dev/images/v1/u/e/illumina-completes-spin-off-of-2498296.jpg)
Illumina Completes Spin-Off Of GRAIL
On June 25, 2024, Illumina, Inc. (NASDAQ: ILMN, $208.92, Market Capitalization: $18.51 billion) announced the completion of the tax free spin-off of GRAIL, Inc. (NASDAQ: GRAL, $36.84, Market Capitaliz...
![](https://cdn.snapi.dev/images/v1/t/c/medical9-2493983.jpg)
Grail bets big on flagship cancer test after spin-off from Illumina
U.S. cancer diagnostic test maker Grail, which will list its shares on the Nasdaq on Tuesday after being spun out of Illumina , is betting that commercial partnerships with health systems, employers a...
![](https://cdn.snapi.dev/images/v1/o/s/press2-2493806.jpg)
Illumina completes the divestiture of GRAIL
GRAIL spin-off complete; GRAIL to begin regular way trading as "GRAL" on June 25 Illumina to issue second quarter 2024 results on August 6; leadership to present Strategy Update on August 13 SAN DIEGO...
![](https://cdn.snapi.dev/images/v1/g/y/illumina-to-spin-off-grail-uni-2473783.jpg)
Illumina To Spin-Off GRAIL Unit On June 24
On June 3, 2024, Illumina's (NASDAQ: ILMN, $109.82, Market Capitalization: $17.5 billion) board of directors approved the spin-off of its wholly owned subsidiary GRAIL, Inc. and shared the details on ...
![](https://cdn.snapi.dev/images/v1/a/u/press7-2473323.jpg)
Illumina DRAGEN v4.3 powers most comprehensive, accurate genome with industry-leading innovations
Latest version includes a prebuilt pangenome capturing more genetic diversity, reducing ancestry bias, and improving accuracy SAN DIEGO , June 11, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a ...
![](https://cdn.snapi.dev/images/v1/i/4/press11-2470805.jpg)
Illumina Inc. (ILMN): 2024 Company Profile, Product Pipeline Analysis, and Ongoing Clinical Trials Insights
Dublin, June 10, 2024 (GLOBE NEWSWIRE) -- The "Illumina Inc (ILMN) - Product Pipeline Analysis, 2024 Update" company profile has been added to ResearchAndMarkets.com's offering. This report is a sourc...
![](https://cdn.snapi.dev/images/v1/q/2/up-nearly-15-in-a-week-will-il-2470789.jpg)
Up Nearly 15% In A Week Will Illumina Stock Continue To See Higher Levels?
Illumina stock (NASDAQ: ILMN) saw a 7% rise on Thursday, June 6, faring better than its peer — Mettler-Toledo stock – down 1%. The rise in ILMN stock can primarily be attributed to the company's decis...
![](https://cdn.snapi.dev/images/v1/a/6/press4-2461395.jpg)
Illumina launches latest chemistry across most popular mid-throughput sequencers, enabling higher quality and greater speed for customers at lower cost
SAN DIEGO , June 4, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced that it has completed integration of its latest chemist...
![](https://cdn.snapi.dev/images/v1/j/p/wz5np67gvbjxfj4wzxxr7opfhu-2460309.jpg)
Illumina to spin off Grail in June
Illumina , a maker of gene sequencing machines, said on Monday it expected to spin off cancer test maker Grail.
![](https://cdn.snapi.dev/images/v1/a/h/press12-2460225.jpg)
Illumina Board of Directors approves spin-off of GRAIL; declares spin-off dividend of GRAIL shares
"When-issued" trading expected to begin on or about June 12, 2024 Record date for distribution of GRAIL shares will be June 13, 2024 Distribution date for GRAIL shares anticipated to be June 24, 2024 ...
![](https://cdn.snapi.dev/images/v1/n/k/press5-2451663.jpg)
Illumina drives genomic testing as standard of care in oncology through collaborative research presented at ASCO
Studies presented represent key focus areas, including building evidence for clinical utility of comprehensive genomic profiling; overcoming market access barriers, and progressing the whole-genome ap...
![](https://cdn.snapi.dev/images/v1/t/h/press20-2450519.jpg)
Illumina releases 2023 Corporate Social Responsibility Report
SAN DIEGO , May 28, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today published its fifth annual Corporate Social Responsibility ...
![](https://cdn.snapi.dev/images/v1/a/c/press6-2449774.jpg)
Integrated Biosciences Joins Illumina Ventures Labs to Design Novel Therapeutics Targeting the Transcriptome
SAN CARLOS, Calif.--(BUSINESS WIRE)-- #age--Integrated Biosciences, a biotechnology company pioneering the use of synthetic biology and machine learning to develop next-generation therapeutics for age...
![](https://cdn.snapi.dev/images/v1/l/s/press3-2440370.jpg)
Anna Richo joins Illumina's Board of Directors
Ms. Richo brings more than 30 years of global legal, compliance, and regulatory experience to Illumina's Board SAN DIEGO , May 20, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today t...
![](https://cdn.snapi.dev/images/v1/a/l/conf3-2433291.jpg)
Illumina To Webcast Upcoming Investor Conference
SAN DIEGO , May 15, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: Bernstein's 40th Annual Strategic Deci...
![](https://cdn.snapi.dev/images/v1/0/d/press7-2426550.jpg)
GRAIL to Host Capital Markets Day
MENLO PARK, Calif.--(BUSINESS WIRE)--GRAIL, LLC announced today that it will host a virtual Capital Markets Day.
![](https://cdn.snapi.dev/images/v1/0/5/press3-2413468.jpg)
Illumina publicly files Form 10 registration statement ahead of planned divestiture of GRAIL
GRAIL to host Capital Markets Day on May 13, 2024 SAN DIEGO , May 6, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that it has publicly filed a Form 10 registration statement wit...